Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study

Díaz-Soto, Gonzalo; Luis, Daniel Antonio de; Conde-Vicente, Rosa; Izaola-Jáuregui, Olatz; Ramos, Carmen; Romero, Enrique

doi:10.1016/j.diabres.2014.01.019

Cited by 42 publications

(31 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanism of these drugs leading to the increase in the adiponectin levels has not been clarified. Several experimental studies have demonstrated that GLP-1 activity is associated with increased serum adiponectin levels [36,37], but one study reported that use of a GLP-1 analog did not increase adiponectin levels in humans [38]. The present study showed a teneligliptin-dependent increase in the adiponectin levels without changes in BMI.…”

Section: Discussionmentioning

confidence: 65%

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

et al. 2015

View full text Add to dashboard Cite

Incretin hormones have been reported to have cytoprotective actions in addition to their glucose-lowering effects. We evaluated whether teneligliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, affects left ventricular (LV) function in patients with type 2 diabetes mellitus (T2DM). Twenty-nine T2DM patients not receiving any incretin-based drugs were enrolled and prescribed with teneligliptin for 3 months. Compared to baseline levels, hemoglobin A1c levels decreased (7.6 ± 1.0 % to 6.9 ± 0.7 %, p < 0.01) and 1,5-anhydro-D-glucitol levels increased (9.6 ± 7.2 μg/mL to 13.5 ± 8.7 μg/mL, p < 0.01) after treatment. Clinical parameters, including body mass index and blood pressure, did not show any difference before and after treatment. Three months after treatment, there were improvements in LV systolic and diastolic function [LV ejection fraction, 62.0 ± 6.5 % to 64.5 ± 5.0 %, p = 0.01; peak early diastolic velocity/basal septal diastolic velocity (E/e') ratio, 13.3 ± 4.1 to 11.9 ± 3.3, p = 0.01]. Moreover, there was an improvement in endothelial function (reactive hyperemia peripheral arterial tonometry [RH-PAT] index; 1.58 ± 0.47 to 2.01 ± 0.72, p < 0.01). There was a significant negative correlation between changes in the E/e' ratio and RH-PAT values. Furthermore, circulating adiponectin levels increased (27.0 ± 38.5 pg/mL to 42.7 ± 33.2 pg/mL, p < 0.01) without changes in patient body weight. Teneligliptin treatment was associated with improvements in LV function and endothelial functions, and an increase in serum adiponectin levels. These results support the cardio-protective effects of teneligliptin in T2DM patients and increase in serum adiponectin levels.

show abstract

Section: Discussionmentioning

confidence: 65%

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The effect of GLP-1 administration on HOMA has been previously studied [14,15]. In our study, all the three kinds of treatment showed statistically significantly lower insulin resistance and higher insulin secretion compared with baseline.…”

Section: Discussionsupporting

confidence: 49%

“…Only partial results have been published in clinical trials [15,18]. To our knowledge, no studies have addressed the effect of liraglutide on adipokines in newly diagnosed T2DM patients.…”

Section: Discussionmentioning

confidence: 97%

Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This study is the first to demonstrate this causal relationship using ETIrs2KO mice; we showed that chronic treatment with anagliptin enhanced insulin-induced capillary recruitment and interstitial insulin concentrations, thereby improving the skeletal muscle glucose uptake in vivo, by directly acting on endothelial cells via NO-and GLP-1-dependent mechanisms. The findings of our study may be of clinical relevance, as GLP-1R agonists and DPP4 inhibitors have been reported to attenuate insulin resistance in humans [9][10][11]40]. Taken together, these data suggest that anagliptin might be a promising agent to improve skeletal muscle insulin resistance in obese patients with type 2 diabetes.…”

Section: Discussionmentioning

confidence: 48%

“…In addition to these actions, GLP-1R agonists have been reported to attenuate insulin resistance in humans [9][10][11]. Recently, Chai et al demonstrated that a bolus injection of a GLP-1R agonist improved both the muscle microvascular blood volume and skeletal muscle glucose uptake in HF diet-fed rats [12].…”

Section: Introductionmentioning

confidence: 99%

Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice

Satō

Kubota

et al. 2016

Diabetologia

View full text Add to dashboard Cite

Aims/hypothesis Recently, incretin-related agents have been reported to attenuate insulin resistance in animal models, although the underlying mechanisms remain unclear. In this study, we investigated whether anagliptin, the dipeptidyl peptidase 4 (DPP-4) inhibitor, attenuates skeletal muscle insulin resistance through endothelial nitric oxide synthase (eNOS) activation in the endothelial cells. We used endothelium-specific Irs2-knockout (ETIrs2KO) mice, which show skeletal muscle insulin resistance resulting from a reduction of insulin-induced skeletal muscle capillary recruitment as a consequence of impaired eNOS activation. Methods In vivo, 8-week-old male ETIrs2KO mice were fed regular chow with or without 0.3% (wt/wt) DPP-4 inhibitor for 8 weeks to assess capillary recruitment and glucose uptake by the skeletal muscle. In vitro, human coronary arterial endothelial cells (HCAECs) were used to explore the effect of glucagon-like peptide 1 (GLP-1) on eNOS activity. Results Treatment with anagliptin ameliorated the impaired insulin-induced increase in capillary blood volume, interstitial insulin concentration and skeletal muscle glucose uptake in ETIrs2KO mice. This improvement in insulin-induced glucose uptake was almost completely abrogated by the GLP-1 receptor (GLP-1R) antagonist exendin-(9-39). Moreover, the increase in capillary blood volume with anagliptin treatment was also completely inhibited by the NOS inhibitor. GLP-1 augmented eNOS phosphorylation in HCAECs, with the effect completely disappearing after exposure to the protein kinase A (PKA) inhibitor H89. These data suggest that anagliptin treatment enhances insulin-induced capillary recruitment and interstitial insulin concentrations, resulting in improved skeletal muscle glucose Hiroyuki Sato, Naoto Kubota and Tetsuya Kubota contributed equally to this work. Electronic supplementary material The online version of this article

show abstract

Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study

Cited by 42 publications

References 30 publications

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study

Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice

Contact Info

Product

Resources

About